

THE SURPRISES OF MOLECULAR TESTING IN NEUROFIBROMATOSIS TYPE 1: RARE ASSOCIATION BETWEEN TWO MUTATIONAL VARIANTS

Aurora Jurca¹, Codruta Diana Petchesi^{2,3}, Maria Claudia Jurca^{2,3}, Dan Bembea⁴, Alexandru Daniel Jurca^{2*}, Diter Atasi⁵

1. *Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania.*
2. *Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania.*
3. *Regional Center for Medical Genetics Bihor (part of ERN THACA), Bihor County Emergency Clinical Hospital, Oradea, Romania.*
4. *Faculty of Medicine, "Iuliu Hațieganu" University of Medicine and Pharmacy, Cluj-Napoca Romania.*
5. *Department II Medical Clinic, Faculty of Medicine, University "Lucian Blaga of Sibiu", Sibiu Romania.*

ARTICLE INFO

Received:

05 January 2024

Received in revised form:

19 March 2024

Accepted:

21 April 2024

Available online:

28 April 2024

Keywords: Neurofibromatosis type 1, Cone-rod dystrophy, Molecular diagnosis, Rare association

ABSTRACT

Neurofibromatosis 1 (NF1 MIM # 162200) is one of the most prevalent illnesses that is inherited dominantly through autosomes. It is sometimes referred to as von Recklinghausen disease. The main features of this condition include neurocutaneous manifestations including café au lait spots, intertriginous freckling, different types of neurofibromas (cutaneous neurofibromas or plexiform tumors), neurological symptoms, and bone abnormalities. It happens at a rate of 1 in 3000 to 1 in 4000 occurrences. Cone-rod dystrophies are part of a diverse set of retinal dystrophies characterized by destruction to cone and rod cells, resulting in a wide range of clinical symptoms. Multiple genes contribute to the development of cone-rod dystrophy, with over 100 genes found so far. Among them is the CRX gene, which is linked to the autosomal dominant type of the condition. The authors describe a fascinating example of a patient diagnosed with Neurofibromatosis type 1 (NF1) as a baby, who developed myopia and astigmatism at age 15, leading to an unexpected outcome in molecular testing. A molecular DNA examination revealed the presence of two mutational variants: a pathogenic variant in the NF1 gene, c.3871-2A, and a possibly pathogenic variant in the CRX gene c.119G>A. The authors use this instance to demonstrate the unexpected findings from molecular testing in a disorder often diagnosed based on clinical criteria, offering patients expert genetic guidance.

This is an open-access article distributed under the terms of the [Creative Commons Attribution-Non Commercial-Share Alike 4.0 License](https://creativecommons.org/licenses/by/4.0/), which allows others to remix, and build upon the work non commercially.

To Cite This Article: Jurca A, Petchesi CD, Jurca MC, Bembea D, Jurca AD, Atasi D. The Surprises of Molecular Testing in Neurofibromatosis Type 1: Rare Association between Two Mutational Variants. *Pharmacophore*. 2024;15(2):70-8. <https://doi.org/10.51847/QG2iHRJqUL>

Introduction

Neurofibromatosis Type I (NF1) is classified as a neurocutaneous syndrome, alongside von Hippel-Lindau syndrome, Sturge-Weber syndrome, and the tuberous sclerosis complex [1, 2]. The condition is a result of pathogenic mutations in the NF1 gene situated on chromosome 17q11.2. The consequence of these mutations is overstimulation of the RAS/MAPK signaling pathway, leading to neurocutaneous manifestations and bone abnormalities [3]. The hallmark clinical findings include café-au-lait spots and neurofibromas, which can vary in size, number, and location [4, 5]. Along with Gardner syndrome and Cowden syndrome, it is among the most common neoplastic hamartoma syndromes [6]. Penetrance is nearly 100%, and the expression of the disorder differs from one affected family to another and between individuals of the same family. NF1 is a disorder diagnosed in the vast majority of cases clinically, taking into account the clinical criteria proposed by the National Institutes of Health (NIH) in 1988 [7]. As the signs of the disorder appear gradually in evolution and are age-

Corresponding Author: Alexandru Daniel Jurca; Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy University of Oradea, Oradea, Romania. E-mail: alexjurca@yahoo.co.uk

dependent, it is necessary to monitor these patients for several years before a clear diagnosis can be established. By the age of 8 years, approximately 97% of patients are diagnosed based on clinical criteria [8, 9]. Genetic testing is an important criterion for confirming the diagnosis of the disorder and has been introduced in the new re-revised diagnostic criteria in 2021 [10, 11].

Cone-rod dystrophy (CORD) is one of a large group of retinal dystrophies that have a broad spectrum of largely overlapping clinical manifestations; this makes diagnosis and therefore therapeutic approaches difficult [12]. Retinal dystrophies are characterized by an initial loss of central visual acuity and color vision, followed by a loss of peripheral vision. Although the onset of the disorder may occur in the first 10 years of life (usually during school years) with a decrease in visual acuity that does not improve after optical correction with glasses, most cases are diagnosed in adulthood [13]. Subsequently, the rod cells responsible for night vision are also affected. Photophobia and dyschromatopsia may also be associated. More than 90 genes and different patterns of inheritance associated with the condition have now been identified: autosomal dominant, autosomal recessive, or X-linked dominant. Autosomal dominant forms of cone-rod dystrophy (adCORD) involve over 10 known genes, with one of the most prevalent being the Cone-Rod Homeobox gene (CRX, OMIM #602225). The encoded protein is a transcription factor specific to photoreceptors, playing a crucial function in the differentiation and development of photoreceptors. Genetic mutations in this gene result in many abnormalities, including macular dystrophy, cone-rod dystrophy, and Leber's congenital amaurosis [14]. The article aims to present a coincidental association of two mutational variants in two different genes in a patient initially diagnosed with NF1. Although NF1 is clinically diagnosed in most cases, molecular diagnosis can sometimes offer surprises, as in the case of our patient, who was identified with a likely pathogenic mutational variant in the CRX gene. Thus, we submit that a thorough clinical diagnosis combined with a molecular diagnosis provides an accurate diagnosis by identifying possible associated pathologies that would not otherwise have been suspected in the patient. A precise diagnosis is essential for competent, accurate genetic counseling and family screening.

Materials and Methods

Case Report

The authors discuss a 19-year-old patient who was enrolled at the Bihor Regional Center for Medical Genetics and was recommended for genetic counseling by her family doctor in infancy.

Laboratory Investigations

The main lab tests performed involved carbohydrate, lipid (lipids, cholesterol, and triglycerides), protein (serum protein electrophoresis and proteinemia), mineral (phosphatemia, calcemia, and magnesemia) metabolisms, hormonal evaluation, and alpha-fetoprotein.

Imagistic Investigations

They targeted an MRI of the brain, and ocular computer tomography (OCT).

Molecular Investigations

The mother provided written informed consent before participating in the trial. The Illumina MiSeq platform was utilized for next-generation sequencing to analyze coding sequences in genomic DNA. Genomic DNA fragmentation was performed, followed by coding sequence amplification and library generation using the Illumina TruSight One Sequencing Panel kit at the Regional Genomic Centre Timisoara, Romania. Analytical procedures in bioinformatics, such as nitrogen base alignment, initial screening for low-quality reads and probable artifacts, and variant annotation, were carried out with the use of Isis (Analysis Software) 2.5.2.3; BWA (Aligner) 0.7.9a-isis-1.0.1; SAMtools 0.1.18 (r982:295); GATK (v1.6-23-gf0210b3)1.7. Data analysis was conducted via the UCSC Genome Browser, OMIM (Online Mendelian Inheritance in Man), and DGV (Database of Genomic Variants) databases based on existing knowledge. We included all disease-causing variants listed in HGMD®, ClinVar (class 1), and variants having a minor allele frequency (MAF) below 1% in the ExAC database. Only variants correlated with the phenotype for which the patient was referred were reported. Variants were interpreted according to the ACMG guidelines (1).

Results and Discussion

Personal Data

The patient is the second child in the family. Family history: young parents, no consanguineous relationship. The paternal grandfather, the father, and the father's brother have numerous café au lait spots and skin neurofibromas. Past medical history: since birth, she has had six café au lait spots on her chest and abdomen, ranging in size from 7/4 cm to 2/1.5 cm, suggestive of neurofibromatosis. In evolution, the number of café au lait spots increased, and axillary freckles and posterior thoracic neurofibromas were reported. Since the age of 15, she has been registered with the ophthalmology service for myopia and astigmatism and later Lisch nodules. At the age of 16, she had a uni-grand mal seizure lasting about 30 seconds.

Clinical Evaluation of the Patient

Phenotypical traits at the age of 17: normal stature (166 cm) and weight (66 kg). The patient presents with multiple café au

lait spots (more than 10) disseminated over the anterior and posterior thorax, neck, abdomen, upper and lower limbs, thoracic neurofibromas, and axillary freckles (**Figures 1-4**).



Figure 1. Cutaneous neurofibroma



Figure 2. Posterior thoracal café au lait spots



Figure 3. Axillary freckles




Figure 4. Café au lait spots on the lower limbs

Laboratory Investigations

Biochemical, hematological, and hormonal (thyroid hormones) tests were within normal limits, and alpha-fetoprotein, an important tumoral factor, was also normal.

Interdisciplinary Consultations and Imagistic Investigations

Ophthalmological examination revealed the presence of myopia and astigmatism. The visual acuity at the right eye was 0.8 with correction, and 1 with correction at the left eye. At the anterior pole, Lisch nodules are visualized (**Figure 5**) in both eyes. Fundus examination of the eye revealed well-contained optic nerve papillae and normal macular reflex. Optical coherence tomography (OCT Nidek DuoScan 3300) revealed a normal macular profile. The field of vision is within normal limits in both eyes.



a) b)
Figure 5. Lisch nodules. a) right eye. b) left eye.

Brain MRI highlights several oval lesions in the hypersignal T2, FLAIR, and isoseminal T1, in the anterior region of the right mesencephalon (measuring approximately 5-7 mm), in the bilateral thalamus (measuring approximately 9 mm on the right and 7 mm on the left) and in the right capsulo-lenticular region (measuring approximately 5 mm, with the appearance of glioma). All lesions are relatively well delimited, without perilesional edema. The corpus callosum appears slightly hypertrophic but without changes in its signal. Electroencephalography (EEG) did not reveal pathological graphoelements.

Molecular Investigations

Using panel sequencing analysis two mutational variants have been detected: the first one with pathogenic significance in the NF1 gene, and the second in the CRX gene, with likely pathogenic significance.

Regarding the first mutation, a splice site null variant in heterozygous status c.3871-2A>T was found in the NF1 gene, with an 89X coverage in the gene's area. Due to splice site localization is a loss of function variant. This variant is not present in populational databases (without ExAC and GnomAD frequency) thus suggesting that it is not a benign variation in the general population, and is not currently identified in people with NF1. In silico models predicting the effect of DNA modification on the protein estimate a pathogenic effect (6 pathogen predictions from BayesDel_addAF, DANN, EIGEN, FATHMM-MKL, MutationTaster and scSNV-Splicing versus 0 benign prediction). For these reasons, this variant has been classified with pathogenic significance according to the ACMG guide (1).

The second mutation variant, that of the CRX genes is a null missense variant in heterozygous status c.119G>A, with a 224X coverage in the variant region. It is not present in population databases (without frequency ExAC and GnomAD) indicating that it is not a benign variation in the population. In silico models predicting the effect of DNA modification on the protein estimate a pathogenic effect (12 pathogen predictions from BayesDel_addAF, DANN, DEOGEN2, EIGEN, FATHMM-MKL, LIST-S2, M-CAP, MVP, MutationAssessor, mutationTaster, PrimateAI, and SIFT versus 0 benign predicts. Thus, for the reasons described above, this variant has been classified with likely pathogenic significance according to the ACMG guide (1) and must be correlated with the patient's phenotype.

NF1 and CRX Genes

NF1 Gene

The NF1 gene is located on the long arm of chromosome 17 (17q11.2). It is a large gene of about 350 kb in length and contains 55 constitutive exons and 5 alternatively spliced exons [15]. NF1 genes encode neurofibromin, a large protein that consists of six functional domains with a role in regulating intracellular signaling pathways.

Neurofibromin is a regulator of the RAS/MAPK signaling pathway. If it loses its function, out-of-control RAS activity occurs, leading to uncontrolled cell division and the triggering of tumorigenesis by disrupting the cell cycle [16].

The Human Gene Mutation Database (HGMD; <http://www.hgmd.org/>) lists more than 3,600 pathogenic NF1 variants that are found throughout the length of the gene at both the exon and intron levels, affecting the splice region. <http://www.hgmd.org/> [17]. These include microdeletions that may cover the entire NF1 gene; CNVs (copy number variants); frameshift, nonsense, and missense; and splice-site [18]. The prevalence of pathogenic variants in the NF1 gene is over 0.5% (31 different pathogenic variants), but the percentage of extremely rare or privately encountered variants is over 46% [19, 20]. On the other hand, 90% of mutations occur in the intragenic region, with less than 10% being deletions that span the entire gene or are located in lacking genomic regions [21].

CRX Gene

The CRX gene is located on chromosome 19 (19q13.33); it belongs to the homeobox gene family and plays a major role in the development of the brain, cerebellum, eyes, and pineal gland. CRX encodes a cone-rod homeobox protein transcription factor that is a critical K50 homeodomain transcription factor with an important role in the differentiation and proper function of photoreceptors. This protein contains 299 amino acids [22].

The CRX gene is a small 25-kb stretch gene containing four exons [23]. Commonly encountered pathogenic variants are missense and in-frame deletions. More than 45 mutations with retinal damage are currently reported in the literature [12, 24]. Most CRX mutations cause the autosomal dominant form of CORD, accounting for 5–10% of all dominant forms of CORD [15, 25]. Mutations in CRX genes cause a wide range of retinopathies, including retinitis pigmentosa, cone-rod dystrophy, and the dominant form of Leber congenital amaurosis, a disorder that is usually autosomal recessive [26, 27].

Neurofibromatosis

Clinical Aspects

Neurofibromatosis is a multisystem disorder with neurocutaneous involvement. It is characterized by skin changes such as café au lait spots, intertriginous freckles, and the appearance of various neurofibromas in both the central nervous system and the peripheral nervous system. There are several known types of neurofibromatosis: neurofibromatosis type 1, the most common type, present in 90% of cases; neurofibromatosis type 2 or NF2-related schwannomatosis (NF2, MIM #101000), found in 3% of patients; SMARCB1-related schwannomatosis (MIM #162091), and LZTR1-related schwannomatosis (MIM #615670), which occurs much less frequently, less than 1% [28]. Along with Noonan, Costello, Legius, and Cardiofaciocutaneous syndromes, it is part of a large group of RASopathies and is the first condition identified as belonging to this signaling pathway [10, 29]. Neurofibromatosis type 1 occurs as a result of a pathogenic variant in the NF1 gene and is autosomal dominant inherited. In 50% of patients, the disorder occurs spontaneously due to de novo mutations. Penetrance is almost 100%. It is a progressive disorder, with the life expectancy of these patients decreasing by 15% compared to the general population. Our patient meets the criteria for NF1 by presenting multiple café au lait spots, axillary freckles, cutaneous neurofibromas, and cortical gliomas. The molecular diagnosis has detected a pathogenic variant in the NF1 gene.

Cutaneous Manifestations in NF1

Café au lait Spots and Freckling

The first sign that draws attention to the disorder is the presence of café au lait spots since birth. They multiply gradually, become evident in early childhood, and grow in proportion to the body. Another major sign of NF1 is the presence of axillary or inguinal freckling. There are small cutaneous tumors, usually measuring between 2 and 4 mm, in small groups. Compared with café au lait spots, the freckling develops later in evolution, usually by the age of 3-5 years. These skin changes are seen in about 70% of the affected individuals.

Neurofibromas.

Neurofibromas are tumors of the peripheral nerves that cause small, soft papules in the color of the skin or as small subcutaneous nodules [30]. They can be classified into cutaneous neurofibromas and plexiform neurofibromas. Cutaneous neurofibromas appear as soft papules between 1 and 2 cm in size; they usually appear at puberty and then increase in number and size until about 20 years of age. Unlike cutaneous neurofibromas, plexiform tumors pathognomonic for NF1 occur from birth, in about 30% of patients, and have an increased risk of malignant transformation (malignant peripheral nerve sheath tumor, MPNST) [31].

Our patient presents with multiple café au lait spots disseminated on the neck, anterior and posterior thorax, abdomen, buttocks, and lower limbs. Axillary freckles were observed at the age of 11 years when the first cutaneous neurofibroma appeared.

Ocular Manifestations in NF1

NF1 poses difficulties for ophthalmologists in terms of prompt diagnosis, clinical presentation, and therapy. The most representative brain tumor present in patients with NF1 is known to be low-grade optical glioma, which appears in 15% of patients during early childhood [32]. Recent advancements in multimodality imaging in ophthalmology have identified new ocular symptoms in NF1, such as choroidal abnormalities (CA), hyperpigmented patches, and retinal vascular abnormalities. The diagnostic criteria for NF1 have been updated to include the presence of two or more cutaneous neurofibromas as an alternative to the presence of Lisch nodules. Choroidal abnormalities are more common in adults (80–90%). In children, they occur at a much lower rate (60–78.6%), but compared to Lisch nodules, they are much more common [16, 33, 34]. The case presented by the authors shows ocular refractive disorders: myopia and astigmatism, respectively Lisch nodules.

Cerebral Manifestations in NF1

Cerebral gliomas are common and usually asymptomatic, with most of them being accidentally detected on an MRI [1]. Their incidence is between 2 and 5% and can occur at any age. The average age at diagnosis of these brain tumors is 13 years. Young adults with NF1 have a 10- to 50-fold increased risk of developing these deadly cancers [35]. The case presented by the authors has brain gliomas identified by brain MRI at the age of 15. The patient presented with a grand mal seizure episode at the age of 16 years. The epilepsy was probably caused by the lesion of the corpus callosum, its hypertrophy may be due to small lesions that are still not visible on a brain MRI. Electroencephalography did not reveal pathological graphoelements.

Genotype-Phenotype Correlation in NF1

There is currently no clear genotype-phenotype correlation although specialized studies through the described mutational variants attempt to establish a clear genotype-phenotype relationship. In a retrospective study that included 38 patients with NF1, Well *et al.* demonstrated that large deletions encompassing the entire gene are associated with a much more severe clinical phenotype, a more severe tumor burden, and an accelerated tumor growth rate compared to patients who had atypical deletions. The authors recommend close monitoring of these patients to assess tumor progression and the risk of malignant transformation and, if appropriate, recommend drug treatment with MEK inhibitors [36]. Peduto *et al.* also demonstrated that

large gene deletions correlate with a severe phenotype and that not all mutational variants have the same effects. Genotype-phenotype associations are on an upward curve at present, changing at a slower but profound pace the clinical and genetic approach to NF patients [3, 21]. The splice site pathogenic mutation found in our patient has not been documented in populational databases, preventing us from establishing a precise genotype-phenotype correlation.

Treatment

Surgical treatment is the main treatment option for neurofibromas, but the risk of tumor recurrence postoperatively is extremely high [28]. It is still considered the only curative treatment for patients with NF1. Surgical intervention takes into account the size of the NP, its location, growth rate, and radiological features, as well as the general health and well-being of the patient [37].

Drug Therapy

Targeted therapy can have a major impact on the course of the disorder. As such, Ras pathway inhibitors are therapeutic agents used in the treatment of inoperable plexiform tumors in children. In 2020 the US Food and Drug Administration approved the first monoclonal antibody, Selumetinib, an inhibitor of MEK1/2. This treatment represents a turning point in the treatment of inoperable plexiform tumors in children older than 2 years [38]. Another therapeutic agent is Rapamycin, an inhibitor of the mTOR pathway that plays a role in activating AKT, thus being another potential drug used in the treatment of plexiform tumors.

Cone Rod Dystrophies

Inheritance

The majority of current research regarding con/con-tying dystrophies focuses on elucidating the remaining causative genes and their molecular mechanisms, understanding the natural history of the disorder, and setting optimal clinical trial targets. More than 30 CORD-associated genes are currently reported in the RetNet database (<http://www.sph.uth.tmc.edu/retnet/>) [14]. They are monogenic disorders with autosomal dominant (adCORD), autosomal recessive (arCORD), or X-linked (xlCORD) inheritance. Related to adCORD, mutations occurring in 10 genes are described, including the CRX gene [23]. For arCORD 13 genes are identified and there are other loci and chromosomal regions mapped: NF1, 18q21.1-q21.3, 1q12-q24, and 10q26. For the X-linked form, the mutations occur in the alternative terminal exon 15 (ORF15) of the RPGR gene located on the short arm of the X chromosome Xp21.1 [39].

Clinical Aspects

The main characteristic of CORD is retinal pigmentation by pigment deposition, especially in the macular area. While in retinitis pigmentosa (also called cone-rod dystrophy, RCD), rod cell receptors are lost first, in CORD, cone cell photoreceptors loss occurs first. This leads to a gradual decrease in visual acuity, disruption of color vision, and decreased sensitivity in the central visual field; later, there is a loss of peripheral vision and night blindness. Hammel *et al.* state that onset usually occurs in childhood, during the school years, although the diagnosis is usually established in adulthood [13]. In a study including 730 Japanese families with a hereditary retinal disorder, Fujinami-Yokokawa *et al.* identified 18 patients from 13 different families with retinal damage due to mutations in the CRX gene; in these patients, the mean age of onset was 45 years (range 15-77); in one patient, the onset of the disorder was at 15 years; late-onset was reported in one patient aged 45 years [40]. In the case presented by the authors, the patient has a likely pathogenic mutational variant that is currently not correlated with her phenotype; at this age, the patient has no suggestive symptomatology for cone-rod dystrophy. The patient has been under ophthalmological care since the age of 15 for myopia and astigmatism, with no clinical signs of cone-rod dystrophy. However, considering the potential late onset of the disease, proper ophthalmological monitoring is crucial.

Diagnosis of Cone-Rod Dystrophy

It is done based on ophthalmological consultation: fundus examination, OCT, and electroretinogram. The electroretinogram (ffERG) subdivides patients into 3 categories: patients with normal ffERG (MD), patients where cone cells are affected (CD), and patients who have both cone and rod cells affected (CORD) [41]. The case presented by the authors falls into the category of normal ffERG (MD).

Treatment

There is currently no curative therapeutic method to stop the progression of the disorder or restore lost vision. Identification of pathogenic variants in CRX genes is an extremely important step in the management of these patients, facilitating correct genetic counseling, providing prognostic data, and participating in clinical trials [42]. Treatment aims to slow the progression of the disorder, treat complications, and counsel patients to cope with the news of blindness [13]. Currently, the patient is undergoing ophthalmic correction for myopia and astigmatism, with no signs of cone-rod dystrophy. Given the likely pathogenic nature of the identified variant, close ophthalmological monitoring is essential for early detection if symptoms arise.

Genotype-Phenotype Correlation in CORD

Genotype-phenotype correlations are complex: different mutations in the same gene can cause extremely complex and different phenotypes, and on the other hand, mutations in different genes cause relatively identical or similar phenotypes. Also, the symptoms in people with CORD with MD and people with retinitis pigmentosa (RP) sometimes overlap; as the disorder progresses, MD patients may switch to CORD [40, 43, 44]. The mutational variant identified in our patient is exceptionally rare and was described in a study by Carss *et al.* indicating its association with hereditary retinal disorders. Our case underscores the importance of molecular testing, which can reveal unexpected associations between genetic variants in different genes, such as NF1 and CRX, highlighting the necessity of individualized medical management and genetic counseling [45]. In 2022 Oh *et al.* identified the same missense type variant in heterozygous status c.119G>A, in two patients with pigmented paravenous retinochoroidal atrophy without associated NF1. This missense variant, identified in both our case and the cases presented by Oh, has previously been documented as harmful, however, its precise phenotype remains unknown. Due to the allele's extremely low frequency in the general population, it is considered an uncommon variant. In silico methods anticipate the variant to be highly likely to cause disease [46]. The case described by us presents only myopia with astigmatism; the case presented by Oh *et al.* associates pigmented paravenous retinochoroidal atrophy, thus not being able to make an obvious genotype-phenotype correlation.

The Association of NF1 with Cone-Rod Dystrophy

It is extremely rarely reported in the literature. In 1993, Kylstra *et al.* reported the first case associating the two pathologies. In 2012, Zobor *et al.* described a case of NF1 associated with cone-rod dystrophy, but in an autosomal recessive form with a mutation in the CNNM4 gene and amelogenesis imperfecta [47, 48]. The case presented by the authors represents a novel finding, being the first reported instance of the co-occurrence of a pathogenic NF1 variant and a likely pathogenic CRX variant. While the patient currently lacks symptoms of cone-rod dystrophy, the potential for its later onset cannot be ruled out. This underscores the complexity of genetic interactions and the necessity of comprehensive medical surveillance in such cases.

Conclusion

The diagnosis and management of neurofibromatosis often involve clinical evaluation by a complex medical team. Although the clinical diagnosis is very important and essential, it is important to look for other signs that are not consistent with the initial diagnosis. Molecular testing can unveil surprising associations, as evidenced in our case, which presents a rare combination of mutations in the NF1 and CRX genes. While the patient currently shows no symptoms of cone-rod dystrophy, ongoing ophthalmological monitoring is imperative for early detection. This case underscores the importance of personalized medicine, guided by genotypic features, in managing patients with complex genetic conditions like NF1 and cone-rod dystrophy.

Acknowledgments: We are extremely grateful to our colleagues from the Center of Genomic Medicine Timisoara for their sequencing services.

Conflict of interest: None

Financial support: This research was funded (publication fee) by the “Lucian Blaga” University of Sibiu. <https://www.ulbsibiu.ro/ro/>.

Ethics statement: The study was conducted under the Declaration of Helsinki and approved by the Institutional Ethics Committee of Emergency Clinical County Hospital Bihor (protocol code 39652/15.11.2023).

References

1. Friedman JM. Neurofibromatosis 1. 1998 Oct 2 [updated 2022 Apr 21]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1109/>.
2. Jurca CM, Kozma K, Petchesi CD, Zaha DC, Magyar I, Munteanu M, et al. Tuberous sclerosis, type II diabetes mellitus and the PI3K/AKT/mTOR signaling pathways-case report and literature review. *Genes (Basel)*. 2023;14(2):433. doi:10.3390/genes14020433
3. Yoshida Y. Neurofibromatosis 1 (von Recklinghausen Disease). *Keio J Med*. 2023. doi:10.2302/kjm.2023-0013-IR
4. Adil A, Koritala T, Munakomi S, Singh AK. Neurofibromatosis type 1. 2023. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.
5. Farschtschi S, Mautner VF, McLean ACL, Schulz A, Friedrich RE, Rosahl SK. The neurofibromatoses. *Dtsch Arztebl Int*. 2020;117(20):354-60. doi:10.3238/arztebl.2020.0354

6. Jurca CM, Frățilă O, Iliăș T, Jurca A, Cătana A, Moisa C, et al. A new frameshift mutation of *PTEN* gene associated with cowden syndrome-case report and brief review of the literature. *Genes (Basel)*. 2023;14(10):1909. doi:10.3390/genes14101909
7. Neurofibromatosis. Conference statement. National institutes of health consensus development conference. *Arch Neurol*. 1988;45(5):575-8. doi:10.1001/archneur.1988.00520290115023
8. Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. *J Med Genet*. 2007;44(2):81-8. doi:10.1136/jmg.2006.045906
9. DeBella K, Szudek J, Friedman JM. Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. *Pediatrics*. 2000;105(3 Pt 1):608-14. doi:10.1542/peds.105.3.608
10. Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: An international consensus recommendation. *Genet Med*. 2021;23(8):1506-13. doi:10.1038/s41436-021-01170-5
11. Hirbe AC, Gutmann DH. Neurofibromatosis type 1: A multidisciplinary approach to care. *Lancet Neurol*. 2014;13(8):834-43. doi:10.1016/S1474-4422(14)70063-8
12. Gonzalez-Gonzalez LA, Scanga H, Traboulsi E, Nischal KK. Novel clinical presentation of a *CRX* rod-cone dystrophy. *BMJ Case Rep*. 2021;14(4):e233711. doi:10.1136/bcr-2019-233711
13. Hamel CP. Cone rod dystrophies. *Orphanet J Rare Dis*. 2007;2:7. doi:10.1186/1750-1172-2-7
14. Wang L, Qi A, Pan H, Liu B, Feng J, Chen W, et al. A novel *CRX* frameshift mutation causing cone-rod dystrophy in a Chinese family: A case report. *Medicine (Baltimore)*. 2018;97(32):e11499. doi:10.1097/MD.00000000000011499
15. Bergoug M, Doudeau M, Godin F, Mosrin C, Vallée B, Bénédicti H. Neurofibromin structure, Functions and regulation. *Cells*. 2020;9(11):2365. doi:10.3390/cells9112365
16. Mallone F, Alisi L, Lucchino L, Di Martino V, Nebbioso M, Armentano M, et al. Insights into novel choroidal and retinal clinical signs in neurofibromatosis type 1. *Int J Mol Sci*. 2023;24(17):13481. doi:10.3390/ijms241713481
17. Stenson PD, Mort M, Ball EV, Evans K, Hayden M, Heywood S, et al. The human gene mutation database: Towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. *Hum Genet*. 2017;136(6):665-77. doi:10.1007/s00439-017-1779-6
18. Tadini G, Brems H, Legius E. Proposal of new diagnostic criteria. Multidisciplinary approach to neurofibromatosis type 1; 2020. 309-13.
19. Koczkowska M, Chen Y, Callens T, Gomes A, Sharp A, Johnson S, et al. Genotype-phenotype correlation in NF1: Evidence for a more severe phenotype associated with missense mutations affecting NF1 codons 844-848. *Am J Hum Genet*. 2018;102(1):69-87. doi:10.1016/j.ajhg.2017.12.001
20. Koczkowska M, Callens T, Chen Y, Gomes A, Hicks AD, Sharp A, et al. Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: Genotype-phenotype study in neurofibromatosis type 1. *Hum Mutat*. 2020;41(1):299-315.
21. Peduto C, Zanobio M, Nigro V, Perrotta S, Piluso G, Santoro C. Neurofibromatosis type 1: Pediatric aspects and review of genotype-phenotype correlations. *Cancers (Basel)*. 2023;15(4):1217. doi:10.3390/cancers15041217
22. Cui H, Jin X, Yang QH, Qu LH, Hou BK, Li ZH, et al. Various phenotypes of autosomal dominant cone-rod dystrophy with cone-rod homeobox mutation in two Chinese families. *Int J Ophthalmol*. 2022;15(12):1915-23. doi:10.18240/ijo.2022.12.04
23. Hodges MD, Vieira H, Gregory-Evans K, Gregory-Evans CY. Characterization of the genomic and transcriptional structure of the *CRX* gene: Substantial differences between human and mouse. *Genomics*. 2002;80(5):531-42. doi:10.1006/geno.2002.6854
24. Hull S, Arno G, Plagnol V, Chamney S, Russell-Eggitt I, Thompson D, et al. The phenotypic variability of retinal dystrophies associated with mutations in *CRX*, with report of a novel macular dystrophy phenotype. *Invest Ophthalmol Vis Sci*. 2014;55(10):6934-44. doi:10.1167/iovs.14-14715
25. Swain PK, Chen S, Wang QL, Affatigato LM, Coats CL, Brady KD, et al. Mutations in the cone-rod homeobox gene are associated with the cone-rod dystrophy photoreceptor degeneration. *Neuron*. 1997;19(6):1329-36. doi:10.1016/s0896-6273(00)80423-7
26. Clanor PB, Buchholz CN, Hayes JE, Friedman MA, White AM, Enke RA, et al. Structural and functional analysis of the human cone-rod homeobox transcription factor. *Proteins*. 2022;90(8):1584-93. doi:10.1002/prot.26332
27. Perrault I, Hanein S, Gerber S, Barbet F, Dufier JL, Munnich A, et al. Evidence of autosomal dominant Leber congenital amaurosis (LCA) underlain by a *CRX* heterozygous null allele. *J Med Genet*. 2003;40(7):e90. doi:10.1136/jmg.40.7.e90
28. Tamura R. Current understanding of neurofibromatosis type 1, 2, and schwannomatosis. *Int J Mol Sci*. 2021;22(11):5850. doi:10.3390/ijms22115850
29. Jurcă MC, Iuhas OA, Puiu M, Chiriță-Emandi A, Andreescu NI, Petchesi CD, et al. Cardiac-faciocutaneous syndrome - A longitudinal study of a case over 33 years: Case report and review of the literature. *Rom J Morphol Embryol*. 2021;62(2):563-8. doi:10.47162/RJME.62.2.23
30. Messersmith L, Krauland K. Neurofibroma. 2023 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK539707/>.

31. Ehara Y, Yamamoto O, Kosaki K, Yoshida Y. Natural course and characteristics of cutaneous neurofibromas in neurofibromatosis 1. *J Dermatol.* 2018;45(1):53-7. doi:10.1111/1346-8138.14025
32. Pan Y, Hysinger JD, Barron T, Schindler NF, Cobb O, Guo X, et al. NF1 mutation drives neuronal activity-dependent initiation of optic glioma. *Nature.* 2021;594(7862):277-82. doi:10.1038/s41586-021-03580-6
33. Viola F, Villani E, Natacci F, Selicorni A, Melloni G, Vezzola D, et al. Choroidal abnormalities detected by near-infrared reflectance imaging as a new diagnostic criterion for neurofibromatosis 1. *Ophthalmology.* 2012;119(2):369-75. doi:10.1016/j.ophtha.2011.07.046
34. Vagge A, Camicione P, Capris C, Sburlati C, Panarello S, Calevo MG, et al. Choroidal abnormalities in neurofibromatosis type 1 detected by near-infrared reflectance imaging in paediatric population. *Acta Ophthalmol.* 2015;93(8):e667-71. doi:10.1111/aos.12750
35. Sellmer L, Farschtschi S, Marangoni M, Heran MK, Birch P, Wenzel R, et al. Non-optic glioma in adults and children with neurofibromatosis 1. *Orphanet J Rare Dis.* 2017;12(1):34. doi:10.1186/s13023-017-0588-2
36. Well L, Döbel K, Kluwe L, Bannas P, Farschtschi S, Adam G, et al. Genotype-phenotype correlation in neurofibromatosis type-1: NF1 whole gene deletions lead to high tumor-burden and increased tumor-growth. *PLoS Genet.* 2021;17(5):e1009517. doi:10.1371/journal.pgen.1009517
37. Mukhopadhyay S, Maitra A, Choudhury S. Selumetinib: The first ever approved drug for neurofibromatosis-1 related inoperable plexiform neurofibroma. *Curr Med Res Opin.* 2021;37(5):789-94. doi:10.1080/03007995.2021.1900089
38. Armstrong AE, Belzberg AJ, Crawford JR, Hirbe AC, Wang ZJ. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas. *BMC Cancer.* 2023;23(1):553. doi:10.1186/s12885-023-10996-y
39. Lu QK, Zhao N, Lv YS, Gong WK, Wang HY, Tong QH, et al. A novel CRX mutation by whole-exome sequencing in an autosomal dominant cone-rod dystrophy pedigree. *Int J Ophthalmol.* 2015;8(6):1112-7. doi:10.3980/j.issn.2222-3959.2015.06.06
40. Fujinami-Yokokawa Y, Fujinami K, Kuniyoshi K, Hayashi T, Ueno S, Mizota A, et al. Clinical and genetic characteristics of 18 patients from 13 Japanese families with CRX-associated retinal disorder: Identification of genotype-phenotype association. *Sci Rep.* 2020;10(1):9531. doi:10.1038/s41598-020-65737-z
41. Birtel J, Eisenberger T, Gliem M, Müller PL, Herrmann P, Betz C, et al. Clinical and genetic characteristics of 251 consecutive patients with macular and cone/cone-rod dystrophy. *Sci Rep.* 2018;8(1):4824. doi:10.1038/s41598-018-22096-0
42. Georgiou M, Fujinami K, Michaelides M. Inherited retinal diseases: Therapeutics, clinical trials and end points-A review. *Clin Exp Ophthalmol.* 2021;49(3):270-88. doi:10.1111/ceo.13917
43. Boulanger-Scemama E, El Shamieh S, Démontant V, Condroyer C, Antonio A, Michiels C, et al. Next-generation sequencing applied to a large French cone and cone-rod dystrophy cohort: Mutation spectrum and new genotype-phenotype correlation. *Orphanet J Rare Dis.* 2015;10:85. doi:10.1186/s13023-015-0300-3
44. Thiadens AA, Phan TM, Zekveld-Vroon RC, Leroy BP, van den Born LI, Hoyng CB, et al. Clinical course, genetic etiology, and visual outcome in cone and cone-rod dystrophy. *Ophthalmology.* 2012;119(4):819-26. doi:10.1016/j.ophtha.2011.10.011
45. Carss KJ, Arno G, Erwood M, Stephens J, Sanchis-Juan A, Hull S, et al. Comprehensive rare variant analysis via whole-genome sequencing to determine the molecular pathology of inherited retinal disease. *Am J Hum Genet.* 2017;100(1):75-90. doi:10.1016/j.ajhg.2016.12.003
46. Oh JK, Nuzbrokh Y, Lee W, Lima de Carvalho JR Jr, Wang NK, Sparrow JR, et al. A mutation in CRX causing pigmented paravenous retinochoroidal atrophy. *Eur J Ophthalmol.* 2022;32(1):NP235-9. doi:10.1177/1120672120957599
47. Zobor D, Kaufmann DH, Weckerle P, Sauer A, Wissinger B, Wilhelm H, et al. Cone-rod dystrophy associated with amelogenesis imperfecta in a child with neurofibromatosis type 1. *Ophthalmic Genet.* 2012;33(1):34-8. doi:10.3109/13816810.2011.592178
48. Kylstra JA, Aylsworth AS. Cone-rod retinal dystrophy in a patient with neurofibromatosis type 1. *Can J Ophthalmol.* 1993;28(2):79-80.